Dechra Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Dechra Pharmaceuticals PLC
Public
Traded asLSEDPH
IndustryPharmaceuticals
Founded1997
Headquarters,
Key people
Tony Rice, (Chairman)
Ian Page, (CEO)
Revenue£481.8 million (2019)[1]
£127.4 million (2019)[1]
£30.9 million (2019)[1]
Websitewww.dechra.com

Dechra Pharmaceuticals PLC is an England-based business involved in the development and marketing of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

History[edit]

The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62 million.[3] In 2010 it based Florida-based DermaPet for US$64 million[4] and Sussex-based Genitrix for £5 million.[5]

It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[6]

Operations[edit]

The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[7]

See also[edit]

References[edit]

  1. ^ a b c "Annual Report 2019". Dechra Pharmaceuticals. Retrieved 1 March 2020.
  2. ^ a b Montague Private Equity announces sale of VetXX
  3. ^ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015.
  4. ^ "Dechra Pharma buys DermaPet for US$64 mln". Proactive Investors. 22 October 2010. Retrieved 1 March 2020.
  5. ^ "Dechra acquires Sussex-based Genitrix in a £5.4m deal". Business Live. 1 December 2010. Retrieved 1 March 2020.
  6. ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
  7. ^ "Dechra Pharmaceuticals PLC". dechraplc.com. Retrieved 28 March 2015.